Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 70 of 5804
-
New combo therapy aims to cure hepatitis b in over half of patients
Disease control Recruiting nowHepatitis B virus (HBV) infection is a major public health threat in China. At present, a functional cure, also known as clinical cure or sustained Hepatitis B surface antigen (HBsAg) loss, is recommended as the ideal endpoint of HBV treatment. However, HBsAg loss can be achieved…
Phase: PHASE2 • Sponsor: The Second Affiliated Hospital of Chongqing Medical University • Aim: Disease control
Last updated Jun 26, 2026 15:29 UTC
-
New trial zaps spreading colon cancer with precision: could it be a Game-Changer?
Disease control Recruiting nowThis phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for patients who are not participating in a s…
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New pill could slash heart risks for millions
Disease control OngoingThis is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in participants with high cardiovascular risk. The primary objective is to evaluate the efficacy of…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug targets Hard-to-Treat breast cancer in advanced stage
Disease control OngoingISIdE is an European, multicentric study that aims to assess the efficacy of Sacituzumab Govitecan (SG) in locally advanced or metastatic triple-negative breast cancer where the disease has progressed despite chemotherapy or within 6 months after the end of curative treatments in…
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New pill aims to keep breast cancer from coming back
Disease control Recruiting nowThis is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therap…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for rare blood cancer: Two-Drug combo trial launches
Disease control Recruiting nowPart 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for part 2 study. Part 2 (Efficacy and Safety): This is a 3 Arm study. Patients wi…
Phase: PHASE3 • Sponsor: Acrotech Biopharma Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Artificial pancreas with two hormones could ease diabetes management
Disease control CompletedThis study is a 12 month open-label, two-arm randomised parallel-group trial in adult type 1 diabetes patients executed in 14 centres in the Netherlands. The aim of this study is to determine the long-term clinical effectiveness of treatment with a dual-hormone (insulin and gluca…
Phase: NA • Sponsor: UMC Utrecht • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
CAR-T therapy takes on tough lymphoma in Head-to-Head trial
Disease control OngoingThis trial will compare tisagenlecleucel to standard of care in adult participants with relapsed or refractory (r/r) follicular lymphoma.
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Could a bone marrow transplant free kidney patients from lifelong drugs?
Disease control OngoingThis study will examine the safety and effectiveness of a bone marrow transplant after kidney transplant (from either a living or deceased donor). An investigational medication and other treatments will be given prior to and after the transplant to help protect the transplanted k…
Phase: PHASE1, PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Ketamine vs. ECT: which stops suicidal thoughts faster?
Disease control ENROLLING_BY_INVITATIONThis study is a randomized open-label single-blind non-inferiority comparative effectiveness study of ECT vs. KET for the treatment of Acute Suicidal Depression (ASD).
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New Alpha-Particle therapy targets Hard-to-Treat tumors
Disease control Recruiting nowThis study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors
Phase: PHASE1, PHASE2 • Sponsor: Perspective Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New melanoma drug aims to match Keytruda's success
Disease control CompletedThe goal of this double-blind, randomized study is to establish the equivalence of the efficacy, safety and immunogenicity of the drugs RPH-075 (international nonproprietary name (INN) is pembrolizumab) and Keytruda® (INN is pembrolizumab) when used in patients with unresectable …
Phase: PHASE3 • Sponsor: R-Pharm • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug combo aims to outdo chemo for advanced bladder cancer
Disease control OngoingThis study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than plati…
Phase: PHASE3 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Could a vaccine finally stop the 'Kissing Disease'?
⭐️ VACCINE ⭐️ CompletedBackground: Epstein-Barr virus (EBV) causes most cases of infectious mononucleosis (mono). Mono can cause fatigue that lasts more than 6 months, and some people can have severe complications. EBV infection may also contribute to some cancers and autoimmune diseases. Currently, t…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:23 UTC
-
New drug could keep cervical cancer away after chemoradiation
Disease control Recruiting nowThis is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New antibiotic cocktail takes on superbugs in phase 3 trial
Disease control CompletedThis study is a multi-center, randomized, single-blind, parallel-group study to assess the efficacy and safety, when nacubactam is coadministered with cefepime or aztreonam, compared with best available therapy (BAT), in the treatment of patients with cUTI, AP, HABP, VABP, and cI…
Phase: PHASE3 • Sponsor: Meiji Seika Pharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for myeloma: experimental drug faces off against standard combo in major trial
Disease control Recruiting nowThis study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and needed to be treated again after many o…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New drug cocktail aims to beat aggressive lymphoma
Disease control OngoingThe purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymp…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene therapy aims to restore hearing in children with rare genetic deafness
Disease control Recruiting nowPart A of this trial will evaluate the safety and tolerability of a single surgical administration procedure in one or both ear(s) with one of two dose levels of AAVAnc80-hOTOF and will evaluate the Akouos Delivery Device, together with the Precision Delivery Mechanism, to safely…
Phase: PHASE1, PHASE2 • Sponsor: Akouos, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Could a shorter, less toxic treatment be just as effective for early breast cancer?
Disease control Recruiting nowThis phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It s…
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC